Utomilumab

Generic Name: Utomilumab

Drug Type: Biotech

CAS Number: 1417318-27-4

Unique Ingredient Identifier: 6YY8O697VF

Background: Utomilumab is under investigation in clinical trial NCT03318900 (T Cell Immunotherapy for Advanced Ovarian Cancer).

Clinical Trials

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Phase 3

Active, not recruiting

Conditions: Advanced Malignancies
NSCLC
Ovarian Cancer
Urothelial Cancer
Solid Tumors

Interventions: Drug: Avelumab
Drug: CMP 001
Drug: Lorlatanib
Drug: Talazoparib
Drug: Pemetrexed
Drug: Axitinib
Drug: Utomilumab
Drug: PF04518600

First Posted Date: 2021-09-28

Last Posted Date: 2024-11-13

Lead Sponsor: Pfizer

Target Recruit Count: 67

Registration Number: NCT05059522

Locations: 🇺🇸
Highlands Oncology Group, PA, Springdale, Arkansas, United States
🇷🇺
Budgetary Healthcare Institution of Omsk Region "Clinical Oncology Dispensary", Omsk, Omskaya Oblast', Russian Federation
🇺🇸
MSK Monmouth, Middletown, New Jersey, United States

and more 66 locations

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

Phase 2

Recruiting

Conditions: Stage IIIB Breast Cancer
Stage III Breast Cancer
Stage IV Breast Cancer
Invasive Breast Carcinoma
Recurrent Breast Carcinoma
Triple-Negative Breast Carcinoma
Unresectable Breast Carcinoma
Stage IIIA Breast Cancer
Stage IIIC Breast Cancer

Interventions: Biological: Anti-OX40 Antibody PF-04518600
Drug: Avelumab
Biological: Utomilumab
Drug: Sacituzumab Govitecan
Drug: Binimetinib
Drug: Liposomal Doxorubicin

First Posted Date: 2019-06-03

Last Posted Date: 2025-05-02

Lead Sponsor: Laura Huppert, MD, BA

Target Recruit Count: 150

Registration Number: NCT03971409

Locations: 🇺🇸
O'Neal Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
Georgetown University, Washington, District of Columbia, United States

and more 9 locations

Rituximab + Immunotherapy in Follicular Lymphoma

Phase 1

Terminated

Conditions: Follicular Lymphoma

Interventions: Drug: Rituximab
Drug: PF04518600
Drug: Utomilumab
Drug: Avelumab

First Posted Date: 2018-08-17

Last Posted Date: 2025-02-06

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 24

Registration Number: NCT03636503

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Washington University in St. Louis, Saint Louis, Missouri, United States

and more 3 locations

Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

Phase 1

Completed

Conditions: Recurrent Mantle Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Refractory Mantle Cell Lymphoma
Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Ibrutinib
Drug: Avelumab
Drug: Carboplatin
Drug: Etoposide Phosphate
Biological: Utomilumab
Drug: Ifosfamide
Other: Laboratory Biomarker Analysis
Biological: Rituximab

First Posted Date: 2018-02-22

Last Posted Date: 2025-03-26

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 16

Registration Number: NCT03440567

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

Phase 2

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Vinorelbine
Drug: Trastuzumab
Drug: Avelumab
Drug: Utomilumab

First Posted Date: 2018-01-30

Last Posted Date: 2024-11-06

Lead Sponsor: Adrienne G. Waks

Target Recruit Count: 100

Registration Number: NCT03414658

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

and more 14 locations

4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer

Phase 1

Completed

Conditions: HER2 Positive Breast Carcinoma
Recurrent Breast Carcinoma
Stage III Breast Cancer
Stage IIIA Breast Cancer
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Stage IV Breast Cancer

Interventions: Drug: Utomilumab
Drug: Trastuzumab
Drug: Ado-Trastuzumab Emtansine

First Posted Date: 2017-12-06

Last Posted Date: 2022-10-19

Lead Sponsor: George W. Sledge Jr.

Target Recruit Count: 18

Registration Number: NCT03364348

Locations: 🇺🇸
Stanford University, School of Medicine, Palo Alto, California, United States

T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer

Phase 1

Completed

Conditions: COL6A3 Positive
HLA-A*0201 Positive Cells Present
Recurrent Ovarian Carcinoma
PRAME Positive

Interventions: Biological: Aldesleukin
Drug: CD8-Positive T-Lymphocyte
Drug: Cyclophosphamide
Procedure: Leukapheresis
Biological: Utomilumab

First Posted Date: 2017-10-24

Last Posted Date: 2024-11-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 5

Registration Number: NCT03318900

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer

Phase 1

Active, not recruiting

Conditions: Metastatic Colorectal Carcinoma
Stage IV Colorectal Cancer AJCC v8
Stage IVA Colorectal Cancer AJCC v8
Stage IVB Colorectal Cancer AJCC v8
Stage IVC Colorectal Cancer AJCC v8

Interventions: Biological: Cetuximab
Drug: Irinotecan Hydrochloride
Other: Pharmacodynamic Study
Biological: Utomilumab

First Posted Date: 2017-09-25

Last Posted Date: 2025-05-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 42

Registration Number: NCT03290937

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer

Phase 2

Terminated

Conditions: Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites
Malignant Neoplasms of Lip Oral Cavity and Pharynx
Oropharyngeal Cancer

Interventions: Drug: Utomilumab
Biological: ISA101b

First Posted Date: 2017-08-22

Last Posted Date: 2022-12-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 3

Registration Number: NCT03258008

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

Phase 1

Active, not recruiting

Conditions: Advanced Malignant Solid Neoplasm
Castration-Resistant Prostate Carcinoma
Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm
Metastatic Prostate Carcinoma
Prostate Carcinoma Metastatic in the Bone
Refractory Malignant Solid Neoplasm
Stage IV Prostate Cancer AJCC v8
Stage IVA Prostate Cancer AJCC v8
Stage IVB Prostate Cancer AJCC v8

Interventions: Drug: Avelumab
Biological: Ivuxolimab
Radiation: Radiation Therapy
Biological: Utomilumab

First Posted Date: 2017-07-14

Last Posted Date: 2025-04-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 173

Registration Number: NCT03217747

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy